Angiogenic microRNA-210 is present in cells surrounding osteonecrosis

Journal of Orthopaedic Research

Volumn 30, Issue 8, 2012, Pages 1263-1270

  Yamasaki, Keiichiro ^a   Nakasa, Tomoyuki ^a   Miyaki, Shigeru ^a   Yamasaki, Takuma ^a   Yasunaga, Yuji ^a   Ochi, Mitsuo ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

angiogenesis; femoral head; microRNA 210; osteonecrosis

Indexed keywords

GELATINASE A; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MATRILYSIN; MICRORNA 210; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FEMUR HEAD NECROSIS; HIP OSTEOARTHRITIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 7; MICRORNAS; MIDDLE AGED; OSTEOARTHRITIS, HIP; OSTEONECROSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON WILLEBRAND FACTOR;

EID: 84862758423     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.22079     Document Type: Article

References (63)

1. Cruess RL, Ross D, Crawshaw E,. 1975. The etiology of steroid-induced avascular necrosis of bone. A laboratory and clinical study. Clin Orthop Relat Res 113: 178-183.
2. Hungerford DS, Zizic TM,. 1978. Alcoholism associated ischemic necrosis of the femoral head. Early diagnosis and treatment. Clin Orthop Relat Res 130: 144-153.
3. Casey BH, Hamilton HW, Bobechko WP,. 1972. Reduction of acutely slipped upper femoral epiphysis. J Bone Joint Surg Br 54: 607-614.
4. Csuka M, Brewer BJ, Lynch KL, et al. 1987. Osteonecrosis, fractures, and protrusio acetabuli secondary to x-irradiation therapy for prostatic carcinoma. J Rheumatol 14: 165-170.
5. Iwegbu CG, Fleming AF,. 1985. Avascular necrosis of the femoral head in sickle-cell disease. A series from the Guinea Savannah of Nigeria. J Bone Joint Surg Br 67: 29-32.
6. Amstutz HC, Carey EJ,. 1966. Skeletal manifestations and treatment of Gaucher's disease. Review of twenty cases. J Bone Joint Surg Am 48: 670-701.
7. Shinoda S, Hasegawa Y, Kawasaki S, et al. 1997. Magnetic resonance imaging of osteonecrosis in divers: comparison with plain radiographs. Skeletal Radiol 26: 354-359.
8. Chandler FA,. 1949. Coronary disease of the hip. J Int Coll Surg 11: 34-36.
9. Arlet J,. 1992. Nontraumatic avascular necrosis of the femoral head: past, present and future. Clin Orthop 277: 12-21.
10. Chen WL, Lin CT, Yao CC, et al. 2006. In-vitro effects of dexamethasone on cellular proliferation, apoptosis, and Na+-K+-ATPase activity of bovine corneal endothelial cells. Ocul Immunol Inflamm 14: 215-223.
11. Kerachian MA, Harvey EJ, Cournoyer D, et al. 2006. Avascular necrosis of the femoral head: vascular hypotheses. Endothelium 13: 237-244.
12. Hong JM, Kim TH, Kim HJ, et al. 2010. Genetic association of angiogenesis- and hypoxia-related gene polymorphisms with osteonecrosis of the femoral head. Exp Mol Med 42: 376-385.
13. Zhang C, Yang F, Cornelia R, et al. 2011. Hypoxia-inducible factor-1 is a positive regulator of Sox9 activity in femoral head osteonecrosis. Bone 48: 507-513.
14. Glowacki J,. 1998. Angiogenesis in fracture repair. Clin Orthop Relat Res Suppl 355: S82-S89.
15. Lewis JS, Lee JA, Underwood JC, et al. 1999. Macrophage responses to hypoxia: relevance to disease mechanisms. J Leukoc Biol 66: 889-900.
16. Ambros V,. 2004. The functions of animal microRNAs. Nature 431: 350-355.
17. Bartel DP,. 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
18. Farh KK, Grimson A, Jan C, et al. 2005. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science 310: 1817-1821.
19. Lagos-Quintana M, Rauhut R, Lendeckel W, et al. 2001. Identification of novel genes coding for small expressed RNAs. Science 294: 853-858.
20. Lee RC, Ambros V,. 2001. An extensive class of small RNAs in Caenorhabditis elegans. Science 294: 862-864.
21. Lau NC, Lim LP, Weinstein EG, et al. 2001. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 294: 858-862.
22. Tsai KW, Hu LY, Wu CW, et al. 2010. Epigenetic regulation of miR-196b expression in gastric cancer. Genes Chromosomes Cancer 49: 969-980.
23. De Santis G, Ferracin M, Biondani A, et al. 2010. Altered miRNA expression in T regulatory cells in course of multiple sclerosis. J Neuroimmunol 226: 165-171.
24. Townley-Tilson WH, Callis TE, Wang D,. 2010. MicroRNAs 1,133 and 206: critical factors of skeletal and cardiac muscle development, function, and disease. Int J Biochem Cell Biol 42: 1252-1255.
25. Krützfeldt J, Rajewsky N, Braich R, et al. 2005. Silencing of microRNAs in vivo with 'antagomirs'. Nature 438: 685-689.
26. Yang B, Lin H, Xiao J, et al. 2007. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 13: 486-491.
27. Ma L, Reinhardt F, Pan E, et al. 2010. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol 28: 341-347.
28. Tazawa H, Tsuchiya N, Izumiya M, et al. 2007. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci USA 104: 2-7.
29. Nakasa T, Ishikawa M, Shi M, et al. 2010. Acceleration of muscle regeneration by local injection of muscle-specific microRNAs in rat skeletal muscle injury model. J Cell Mol Med 2495: 2-5.
30. Takeshita F, Patrawala L, Osaki M, et al. 2010. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther 18: 181-187.
31. Poliseno L, Tuccoli A, Mariani L, et al. 2006. MicroRNAs modulate the angiogenic properties of HUVECs. Blood 108: 3068-3071.
32. Kuehbacher A, Urbich C, Zeiher AM, et al. 2007. Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. Circ Res 101: 59-68.
33. Suárez Y, Fernández-Hernando C, Pober JS, et al. 2007. Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ Res 100: 1164-1173.
34. Fish JE, Santoro MM, Morton SU, et al. 2008. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 15: 272-284.
35. van Solingen C, Seghers L, Bijkerk R, et al. 2009. Antagomirmediated silencing of endothelial cell specific microRNA-126 impairs ischemia-induced angiogenesis. J Cell Mol Med 13: 1577-1585.
36. Dews M, Homayouni A, Yu D, et al. 2006. Augmentation of tumor angiogenesis by aMyc-activated microRNA cluster. Nat Genet 38: 1060-1065.
37. Chen Y, Gorski DH,. 2008. Regulation of angiogenesis through a microRNA(miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood 111: 1217-1226.
38. Fasanaro P, D'Alessandra Y, Di Stefano V, et al. 2008. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem 283: 15878-15883.
39. Lee DY, Deng Z, Wang CH, et al. 2007. MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc Natl Acad Sci USA 104: 20350-20355.
40. Würdinger T, Tannous BA, Saydam O, et al. 2008. miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell 14: 382-393.
41. Wu WK, Law PT, Lee CW, et al. 2011. MicroRNA in colorectal cancer: from benchtop to bedside. Carcinogenesis 32: 247-253.
42. Wahid F, Shehzad A, Khan T, et al. 2010. MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta 1803: 1231-1243.
43. Mack GS,. 2007. MicroRNA gets down to business. Nat Biotechnol 25: 631-638.
44. Iguchi H, Kosaka N, Ochiya T,. 2010. Versatile applications of microRNA in anticancer drug discovery: from therapeutics to biomarkers. Curr Drug Discov Technol 7: 95-105.
45. Sugano N, Atsumi T, Ohzono K, et al. 2002. The 2001 revised criteria for diagnosis, classification, and staging of idiopathic osteonecrosis of the femoral head. J Orthop Sci 7: 601-605.
46. Huang X, Ding L, Bennewith KL, et al. 2009. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell 35: 856-867.
47. Liu Y, Cox SR, Morita T, et al. 1995. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells: identification of a 5' enhancer. Circ. Res 77: 638-643.
48. Fasanaro P, Greco S, Lorenzi M, et al. 2009. An integrated approach for experimental target identification of hypoxia-induced miR-210. J Biol Chem 284: 35134-35143.
49. Greither T, Grochola LF, Udelnow A, et al. 2010. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer 126: 73-80.
50. Kulshreshtha R, Ferracin M, Wojcik SE, et al. 2007. A microRNA signature of hypoxia. Mol Cell Biol 27: 1859-1867.
51. Saini HK, Griffiths-Jones S, Enright AJ,. 2007. Genomic analysis of human microRNA transcripts. Proc Natl Acad Sci USA 104: 17719-17724.
52. Zhang Z, Sun H, Dai H, et al. 2009. MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT. Cell Cycle 8: 2756-2768.
53. Camps C, Buffa FM, Colella S, et al. 2008. hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 14: 1340-1348.
54. Kaelin WG, Ratcliffe PJ,. 2008. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 30: 393-402.
55. Crosby ME, Kulshreshtha R, Ivan M, et al. 2009. MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res 69: 1221-1229.
56. Huang X, Ding L, Bennewith KL, et al. 2009. Hypoxia-inducible miR-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell 35: 856-867.
57. Kim HW, Haider HK, Jiang S, et al. 2009. Ischemic preconditioning augments survival of stem cells via miR-210 expression by targeting caspase-8-associated protein 2. J Biol Chem 284: 33161-33316 8.
58. Jewell UR, Kvietikova I, Scheid A, et al. 2001. Induction of HIF-1α in response to hypoxia is instantaneous. FASEB J 15: 1312-1314.
59. Wood SM, Gleadle JM, Pugh CW, et al. 1996. The role of the aryl hydrocarbon receptor nuclear translocator (ARNT) in hypoxic induction of gene expression. Studies in ARNT-deficient cells. J Biol Chem 271: 15117-15123.
60. Ribatti D, Vacca A, Dammacco F,. 2004. VEGF and tumor progression in human melanoma. In:, Harmey JH, editor. VEGF and cancer. New York: Eurekah.com and Kluwer Academic/Plenum. pp. 48-53.
61. Ribatti D, Vacca A, Dammacco F,. 1999. The role of the vascular phase in solid tumor growth: a historical review. Neoplasia 1: 293-302.
62. Qutub AA, Mac Gabhann F, Karagiannis ED, et al. 2009. Multiscale models of angiogenesis. IEEE Eng Med Biol Mag 28: 14-31.
63. Varoga D, Drescher W, Pufe M, et al. 2009. Differential expression of vascular endothelial growth factor in glucocorticoid-related osteonecrosis of the femoral head. Clin Orthop Relat Res 467: 3273-3282.